Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
mercredi, octobre 21
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
AbCellera Biologics Inc
ABCL
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$11.71
-0.22
-1.84%
Dern. MÀJ: Oct 20, 7:32 PM
$11.72
-0.21
-1.76%
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Options
Rapport sur les stocks
Privacy Manager
AbCellera Biologics Financials
AbCellera Biologics (ABCL) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
AbCellera Biologics Q2 EPS $(0.18) Misses $(0.14) Estimate, Sales $4.050M Miss $7.784M Estimate
AbCellera Biologics (NASDAQ:ABCL) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $(0.14) by 28.57 percent. This is a 50 percent decrease over losses of $(0.12) per share
Benzinga Newsdesk
PRO
AbCellera Biologics Q1 EPS $(0.14) Beats $(0.20) Estimate, Sales $8.315M Beat $5.856M Estimate
AbCellera Biologics (NASDAQ:ABCL) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.20) by 30 percent. This is unchanged from the same period last year. The company reported
Benzinga Newsdesk
Earnings Scheduled For May 11, 2026
Benzinga Insights
What Sparked AbCellera Biologics To Soar Over 9% After Hours
AbCellera Biologics shares jumped 9.3% after hours to $3.52 following an 83% earnings beat in Q4 2025.
Mohd Haider
AbCellera Biologics Q4 Earnings Report: What Investors Need to Know
Benzinga Insights
PRO
AbCellera Biologics Q4 EPS $(0.03) Beats $(0.17) Estimate, Sales $44.900M Beat $6.351M Estimate
AbCellera Biologics (NASDAQ:ABCL) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.17) by 82.04 percent. This is a 75 percent increase over losses of $(0.12) per share from
Benzinga Newsdesk
